Canaccord raised the firm’s price target on Penumbra to $235 from $176 and keeps a Buy rating on the shares. The firm updated its model which is simply a correction of their Q1/24 revenue mix for OUS thrombectomy; which had no impact on other segment revenue in Q1/24 nor forward quarter numbers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
Questions or Comments about the article? Write to editor@tipranks.com